Anti-U3 RNP autoantibodies in systemic sclerosis

Arthritis and Rheumatism

Volumn 60, Issue 4, 2009, Pages 1112-1118

  Aggarwal, Rohit ^a   Lucas, Mary ^a   Fertig, Noreen ^a   Oddis, Chester V ^a   Medsger, Thomas A ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RIBONUCLEOPROTEIN ANTIBODY;

ADULT; AFRICAN AMERICAN; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE CLASSIFICATION; DISEASE COURSE; FEMALE; GASTROINTESTINAL SYMPTOM; GROUPS BY AGE; HEART DISEASE; HUMAN; IMMUNOPRECIPITATION; KIDNEY DISEASE; LABORATORY TEST; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORTALITY; MYOPATHY; ORGAN INJURY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SEX DIFFERENCE; SKIN MANIFESTATION; SURVIVAL RATE; SYSTEMIC SCLEROSIS;

ADULT; AFRICAN AMERICANS; AUTOANTIBODIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GASTROINTESTINAL DISEASES; HEART DISEASES; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PULMONARY FIBROSIS; RIBONUCLEOPROTEINS, SMALL NUCLEOLAR; SCLERODERMA, SYSTEMIC; SEROEPIDEMIOLOGIC STUDIES; SEX DISTRIBUTION; SKIN DISEASES; SURVIVAL ANALYSIS;

EID: 65249155937     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.24409     Document Type: Article

References (30)

1. Silver RM, Bolster MB, Medsger TA Jr. Systemic sclerosis (scleroderma) : clinical aspects. In: Koopman WJ, Moreland LW, editors. Arthritis and allied conditions: a textbook of rheumatology. 15th ed. Philadelphia: Lippincott Williams and Wilkins; 2006. p. 1633-80.
2. Tan EM. Autoantibodies to nuclear antigens (ANA) : their immunobiology and medicine. Adv Immunol 1982;33:167-240.
3. Fertig N, Rodriguez-Reyna T, Kuwana M, Medsger TA Jr, Feghali-Bostwick CA. Circulating anti-U11/U12 ribonucleoprotein antibodies in systemic sclerosis are markers of severe lung fibrosis [abstract]. Arthritis Rheum 2006;54 Suppl 9:S745.
4. Reveille JD, Solomon DH, and the American College of Rheumatology Ad Hoc Committee on Immunologic Testing Guidelines. Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. Arthritis Rheum 2003;49:399-412.
5. Okano Y. Antinuclear antibody in systemic sclerosis (scleroderma). Rheum Dis Clin North Am 1996;22:709-35.
6. Bernstein RM, Steigerwald JC, Tan EM. Association of antinuclear and antinucleolar antibodies in progressive systemic sclerosis. Clin Exp Immunol 1982;48:43-51.
7. Kipnis RJ, Craft J, Hardin JA. The analysis of antinuclear and antinucleolar autoantibodies of scleroderma by radioimmunoprecipitation assays. Arthritis Rheum 1990;33:1431-7.
8. Kuwana M, Kaburaki J, Okano Y, Tojo T, Homma M. Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum 1994; 37:75-83.
9. Reimer G, Steen VD, Penning CA, Medsger TA Jr, Tan EM. Correlates between autoantibodies to nucleolar antigens and clinical features in patients with systemic sclerosis (scleroderma). Arthritis Rheum 1988;31:525-32.
10. Riboldi P, Asero R, Origgi L, Crespi S, Meroni PL, Sguotti C, et al. Antinuclear antibodies in progressive systemic sclerosis. Clin Exp Rheumatol 1985;3:205-11.
11. Lischwe MA, Ochs RL, Reddy R, Cook RG, Yeoman LC, Tan EM, et al. Purification and partial characterization of a nucleolar scleroderma antigen (Mr = 34, 000; pI, 8.5) rich in NG, NG- dimethylarginine. J Biol Chem 1985;260:14304-10.
12. Arnett FC, Reveille JD, Goldstein R, Pollard KM, Leaird K, Smith EA, et al. Autoantibodies to fibrillarin in systemic sclerosis (scleroderma) : an immunogenetic, serologic, and clinical analysis. Arthritis Rheum 1996;39:1151-60.
13. Okano Y, Steen VD, Medsger TA Jr. Autoantibody to U3 nucleolar ribonucleoprotein (fibrillarin) in patients with systemic sclerosis. Arthritis Rheum 1992;35:95-100.
14. Pearson DL, Reimonenq RD, Pollard KM. Expression and purification of recombinant mouse fibrillarin. Protein Expr Purif 1999;17:49-56.
15. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
16. Poormoghim H, Lucas M, Fertig N, Medsger TA Jr. Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty-eight patients. Arthritis Rheum 2000;43:444-51.
17. Kao AH, Lacomis D, Lucas M, Fertig N, Oddis CV. Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy. Arthritis Rheum 2004; 50:209-15.
18. Mitri GM, Lucas M, Fertig N, Steen VD, Medsger TA Jr. Comparison between anti-Th/To- and anticentromere antibody-positive systemic sclerosis patients with limited cutaneous involvement. Arthritis Rheum 2003;48:203-9.
19. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis) : classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
20. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:344-7.
21. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
22. Clements PJ, Lachenbruch PA, Seibold JR, Zee B, Steen VD, Brennan P, et al. Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol 1993;20:1892-6.
23. Hesselstrand R, Scheja A, Akesson A. Mortality and causes of death in a Swedish series of systemic sclerosis patients. Ann Rheum Dis 1998;57:682-6.
24. Meyer OC, Fertig N, Lucas M, Somogyi N, Medsger TA Jr. Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis. J Rheumatol 2007;34:104-9.
25. Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005;35:35-42.
26. Baserga SJ, Yang XD, Steitz JA. An intact Box C sequence in the U3 snRNA is required for binding of fibrillarin, the protein common to the major family of nucleolar snRNPs. EMBO J 1991;10:2645-51.
27. Harvey G, Black C, Maddison P, McHugh N. Characterization of antinucleolar antibody reactivity in patients with systemic sclerosis and their relatives. J Rheumatol 1997;24:477-84.
28. Van Eenennaam H, Vogelzangs JH, Bisschops L, Te Boome LC, Seelig HP, Renz M, et al. Autoantibodies against small nucleolar ribonucleoprotein complexes and their clinical associations. Clin Exp Immunol 2002;130:532-40.
29. Tormey VJ, Bunn CC, Denton CP, Black CM. Anti-fibrillarin antibodies in systemic sclerosis. Rheumatology (Oxford) 2001;40: 1157-62.
30. Yang JM, Hildebrandt B, Luderschmidt C, Pollard KM. Human scleroderma sera contain autoantibodies to protein components specific to the U3 small nucleolar RNP complex. Arthritis Rheum 2003;48:210-7.